johncohen- I have a slightly different view. In my opinion- and having spoken to people who know a lot about osl- the problem was osl totally underestimating (or ignorance of) the regulatory requirements and setting up the market in 2014/2015 to believe CE was a breeze and they were in fast track. Then they realised they’d got it wrong, need to do a trial as they didn’t have enough data for CE so off they went to do panco. For a trial of that type the time it took was actually probably about par so I don’t think they were dragging their feet at that stage because you can’t always predict patient recruitment into a trial. Then of course they spent another year having to reverse the CE rejection until finally scraping through last year . But you could also say the company as it existed before the last CEO (Kenny) spent 2 years doing nothing. Or the company in England that designed the original device started development then dropped it for some reason and that’s many many years ago. so it’s a troubled path. And yes in that time other treatments have evolved.
concerning RCT you’re right, I’ve looked at their announcements from last year and $7m raised was supposed to be for US trial. But there’s no design that I’ve seen. They also told market FDA approval for pancreatic cancer in 2022/23 but you can forget that. To meet that date in my opinion they’d have needed to start RCT by 2018. And that’s assuming a positive trial. “Breakthrough” designation otherwise means little. $7million won’t get them a RCT. Depending on patient numbers (I’ve heard 200 or more) I think they’d be looking at costs at least 5 X that amount, and that’s conservative. Could be 10x. . You could go back through their financials to see how much they spent on R&D with panco to help gauge the likely costs involved with larger trial.
- Forums
- ASX - By Stock
- OSL
- Ann: Half Yearly Report and Accounts
Ann: Half Yearly Report and Accounts, page-51
-
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OSL (ASX) to my watchlist
|
|||||
Last
0.5¢ |
Change
-0.001(16.7%) |
Mkt cap ! $16.66M |
Open | High | Low | Value | Volume |
0.5¢ | 0.5¢ | 0.5¢ | $2.867K | 573.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 4186862 | 0.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.6¢ | 15328756 | 23 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 4186862 | 0.005 |
30 | 24439465 | 0.004 |
6 | 4873298 | 0.003 |
6 | 5457516 | 0.002 |
4 | 7800000 | 0.001 |
Price($) | Vol. | No. |
---|---|---|
0.006 | 15328756 | 23 |
0.007 | 29138909 | 20 |
0.008 | 9343848 | 9 |
0.009 | 12462253 | 5 |
0.010 | 6693666 | 5 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online